Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
Mary Catherine G. Pangilinan, Peerada Sermswan, Pravit Asawanonda
Abstract
Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant clearance of lesions. No recurrence or opportunistic infection was noted. In conclusion, anti-IL-17 monoclonal antibodies are an effective and promising treatment option for HIV-infected patients with psoriasis.
Topics & Concepts
PsoriasisMedicineMonoclonal antibodyHuman immunodeficiency virus (HIV)DermatologyDiseaseImmune systemImmunologyAntibodyPathologyPsoriasis: Treatment and PathogenesisAutoimmune Bullous Skin DiseasesImmunodeficiency and Autoimmune Disorders